Advertisement
Advertisement

RARE

RARE logo

Ultragenyx Pharmaceutical Inc.

33.60
USD
Sponsored
-1.01
-2.90%
Jul 10, 14:52 UTC -4
Open

RARE Earnings Reports

Positive Surprise Ratio

RARE beat 20 of 42 last estimates.

48%

Next Report

Date of Next Report
Jul 30, 2026
Estimate for Q2 26 (Revenue/ EPS)
$185.36M
/
-$1.25
Implied change from Q1 26 (Revenue/ EPS)
+36.29%
/
-32.07%
Implied change from Q2 25 (Revenue/ EPS)
+11.33%
/
+6.84%

Ultragenyx Pharmaceutical Inc. earnings per share and revenue

On May 05, 2026, RARE reported earnings of -1.84 USD per share (EPS) for Q1 26, missing the estimate of -1.53 USD, resulting in a -19.49% surprise. Revenue reached 136.00 million, compared to an expected 161.95 million, with a -16.02% difference. The market reacted with a +3.68% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 14 analysts forecast an EPS of -1.25 USD, with revenue projected to reach 185.36 million USD, implying an decrease of -32.07% EPS, and increase of 36.29% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Replimune Group, Inc.
Report Date
Jun 29, 2026 For Q4 26
Estimate
-$0.72
Actual
-$0.76
Surprise
-4.52%
logo
Beyond Air, Inc. Common Stock
Report Date
Jun 26, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.63
Surprise
-9.00%
FAQ
For Q1 2026, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.84, missing estimates by -19.49%, and revenue of $136.00M, -16.02% below expectations.
The stock price moved up 3.68%, changed from $25.01 before the earnings release to $25.93 the day after.
The next earning report is scheduled for Jul 30, 2026.
Based on 14 analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.25 and revenue of $185.36M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement